MedPath

The effect of individualised, vibrotactile neurofeedback training on postural stability in older adults with hearing impairment: a randomised double-blind, placebo-controlled multi centre trial.

Not Applicable
Conditions
Hearing impairment
Ear - Deafness
Registration Number
ACTRN12619000732189
Lead Sponsor
The University of Queensland
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
All
Target Recruitment
207
Inclusion Criteria

Aged 60 years or older
Bilateral four frequency average hearing loss (4FAHL) at 500, 1000, 2000 and 4000 Hz to be between 40 and 90 dB HL, with 4FAHL difference between ears to be no greater than 15 dB HL.
Self-reported dizziness, vertigo or unsteadiness for at least 12mths
A score >20 on Dizziness Handicap Inventory score (DHI)
A composite score of >39 -Geriatric Standard Balance Deficit (gSBDT) test
Residing in the community or low care dwelling

Exclusion Criteria

Severe vision impairment when using glasses (Scoring 0.2 or lower on Landolt-rings test table.
Benign paroxysmal positional vertigo (BPPV) either at the time of screening as determined by a positive Dix-Hallpike maneuver or diagnosis of BPPV within the last 2weeks prior to screening.
History of Meniere’s disease or acoustic neuroma
Medical conditions affecting balance, limiting ability to walk without assistance (e.g. stroke, Parkinson’s disease), or to safely exercise
Cognitive impairment as reflected by a score of <23/30 on the MoCA
Being unable to perform half of the test exercises of the gSBDT (<7 / 14 exercises)
History of drug abuse or alcoholism with the last 2 years
Taking sedative medications (e.g. diazepam) on a daily basis, between the hours of 6am and 6pm.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Postural sway during gait and balance tasks will be measured using the composite score of the Geriatric Standard Balance Deficit Test (gSBDT)[Baseline (week 0), in the week following conclusion of the final intervention session (week 2) ]
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath